Meeting
2023 ASCO Genitourinary Cancers Symposium
Financial toxicity in patients with metastatic renal cell carcinoma on combination therapy.
Authors
Michael D. Staehler
University of Munich, Muenchen, Germany
Michael D. Staehler , Hedyeh Ebrahimi , Ulka N. Vaishampayan , Severin Rodler , Sumanta Monty Pal , Dena Battle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 651)
DOI
10.1200/JCO.2023.41.6_suppl.651
Abstract #
651
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world metastatic renal cell carcinoma (mRCC) treatment trends in Mexico: A public vs private sector analysis.
First Author: Iván Romarico González Espinoza
Poster
2024 ASCO Genitourinary Cancers Symposium
Comparison of financial toxicity among patients with non-metastatic versus metastatic renal cell carcinoma.
First Author: Michael D. Staehler
Poster
2023 ASCO Quality Care Symposium
Total and treatment-related costs of care associated with in patients with metastatic renal cell carcinoma receiving targeted or immune therapy.
First Author: Syed N. Rahman